Galderma’s 2025 report highlights strong momentum for Nemluvio (nemolizumab) and Relfydess (relabotulinumtoxinA), two key innovations driving growth in therapeutic dermatology and injectable aesthetics.
Written By: Sana Khan BPharm
Reviewed By: Pharmacally Editorial Team
Galderma delivered record financial performance in 2025, reporting $5.207 billion in net sales, up 17.7% year-on-year at constant currency, driven by strong growth across both therapeutic dermatology and injectable aesthetics.
Two recently launched products Nemluvio (nemolizumab) and Relfydess (relabotulinumtoxinA) emerged as key contributors, reflecting Galderma’s strategy of combining targeted biologic therapies with next-generation aesthetic technologies to strengthen its global dermatology leadership.
Nemluvio, a monoclonal antibody targeting the interleukin-31 receptor alpha (IL-31RA) pathway, represents a novel approach to treating chronic pruritic inflammatory skin diseases. IL-31 signaling plays a central role in mediating itch and inflammation, particularly in conditions such as prurigo nodularis and atopic dermatitis. By blocking IL-31 receptor signaling, Nemluvio interrupts the neuroimmune itch pathway that drives persistent scratching and skin inflammation.
The therapy gained regulatory approvals in major markets including the United States and Europe following positive results from the OLYMPIA clinical trial program in prurigo nodularis and the ARCADIA Phase III trials in moderate-to-severe atopic dermatitis, which demonstrated significant improvements in itch reduction, skin lesions, and disease severity compared with placebo.
Following its commercial launch, Nemluvio rapidly gained traction, helping Galderma’s Therapeutic Dermatology segment grow more than 50% year-on-year to $1.185 billion in 2025. Reflecting strong early demand and expanding indications, Galderma raised its projected peak annual sales potential for Nemluvio from more than $2 billion to above $4 billion globally.
In parallel, Galderma strengthened its neuromodulator portfolio with the launch of Relfydess (relabotulinumtoxinA), a next-generation botulinum toxin designed for aesthetic indications. The product is developed using Galderma’s PEARL technology and is formulated as a ready-to-use liquid neuromodulator, eliminating the need for reconstitution required by conventional freeze-dried botulinum toxin products.
This formulation is intended to simplify preparation, improve dosing consistency, and streamline clinical workflows in aesthetic practices. Relfydess has been introduced across multiple international markets and has demonstrated strong early adoption among practitioners. The momentum contributed to continued expansion of Galderma’s neuromodulator franchise, with the segment generating $1.471 billion in net sales in 2025, representing 14.3% year-on-year growth, supported by both Dysport and the early launch trajectory of Relfydess.
Galderma highlighted that the launches of Nemluvio and Relfydess represent a strategic evolution of its portfolio toward science-driven dermatology innovation across both medical and aesthetic care.
Nemluvio strengthens the company’s presence in immune-mediated skin diseases by targeting the biological drivers of chronic itch, while Relfydess introduces a differentiated neuromodulator technology aimed at improving procedural efficiency in aesthetic medicine. Together, these therapies are expected to remain central to Galderma’s growth trajectory as the company expands its leadership across the global dermatology market.
Reference
Galderma delivers record 2025 results with net sales of 5.207 billion USD, up 17.7% at constant currency, and Core EBITDA of 1.211 billion USD, growing 18.9% at constant currency, 05 March 2026, Galderma delivers record 2025 results with net sales of 5.207 billion USD, up 17.7% at constant currency, and Core EBITDA of 1.211 billion USD, growing 18.9% at constant currency | Galderma
Galderma’s Nemluvio Shows Sustained Efficacy and Safety in Prurigo Nodularis Up to 3 Years in OLYMPIA LTE Study, 27 February 2026, https://pharmacally.com/galdermas-nemluvio-shows-sustained-efficacy-and-safety-in-prurigo-nodularis-up-to-3-years-in-olympia-lte-study/
A Long-term Study of Nemolizumab (CD14152) in Participants with Prurigo Nodularis (PN), ClinicalTrials.gov ID NCT04204616, https://clinicaltrials.gov/study/NCT04204616
ASDS 2024: new phase III READY-4 data demonstrate long-term safety and efficacy of Galderma’s RelabotulinumtoxinA (Relfydess™), 21 October 2024, https://www.galderma.com/news/asds-2024-new-phase-iii-ready-4-data-demonstrate-long-term-safety-and-efficacy-galdermas
About Writer
Sana Jamil Khan, BPharm
She is a pharmacy graduate with a keen interest in clinical research, pharmacovigilance, and medical writing, with a growing focus on publication and scientific content development. In her words, she is passionate about translating complex medical data into clear, evidence-based communication.